Unravel MGUS

Our Team

The Unravel MGUS study was designed by a team of experienced clinical, research and drug development professionals. The study is actively supported by the leading UK haematologists expert in the identification and management of MGUS.

The study is sponsored by the Human Antibody Factory Limited (HAF). HAF is a semi-virtual organisation leveraging leading scientific expertise with a management team of clinical and drug development professionals.

Trevor Baglin

TREVOR BAGLIN
MB Ph.D FRCP FRCPath

CHIEF INVESTIGATOR


Trevor Baglin is Consultant Haematologist to Cambridge University Hospitals with responsibility for both clinical and laboratory haematology. His main research interests are in personalised risk profiling, the molecular basis of regulation of blood coagulation and drug discovery and development. He was previously the Clinical Director for Pathology and Laboratories at Cambridge University Hospitals. He has worked with biotech and pharma both as an advisor and collaborator and was a Founder-Director of Xo1 Ltd. He has been President of the British Society for Haematology and President of the British Society for Haemostasis and Thrombosis.


PRINCIPAL INVESTIGATORS

Dr Jill Reckless

RxCelerate Ltd


Dr Arun Alfred

Rotherham Hospital


Dr Charles Crawley

Addenbrookes Hospital, Cambridge University Hospitals 


Professor Graham Jackson

Freeman Hospital, Freeman Road


Dr Matthew Streetly

Guys and St Thomas’ NHS Foundation Trust


Dr Cathy Williams

Nottingham City Hospital


Prof Gordon Cook

St James’s Hospital, Leeds


Dr Heather Eve

Torbay Hospital, Torquay


Dr Anand Lokare

Heartlands Hospital, Birmingham


Dr Pratap Neelakantan

Royal Berkshire Hospital, Reading